mynth
06/2016MajorityLBO

PAI Partners takes majority stake in Ethypharm

FRANCE Life Sciences / Pharma & Biotech EV €500M–1.5bn

Context

PAI Partners has entered into a definitive agreement to acquire Ethypharm from Astorg Partners and its Belgian co-investor Sofina. The transaction followed a competitive auction process managed by Rothschild & Cie, where PAI reportedly outbid other major private equity firms and international pharmaceutical groups. The operation marks a successful exit for Astorg, which had held a 60% stake in the company since 2007. The strategic rationale for the acquisition centers on supporting Ethypharm's international expansion and its leadership in specialized therapeutic areas such as pain management and addiction treatment. The transaction was supported by an "all senior" debt financing structure composed of Tranche A and Tranche B facilities. This investment follows a period of significant growth for Ethypharm, which recently expanded its footprint in the United Kingdom through the acquisition of DB Ashbourne. PAI Partners intends to leverage the target's sophisticated galenic technology and established global partnership network to drive further organic and inorganic growth. The deal reflects a significant step up in valuation for the group, highlighting the increased market demand for specialized pharmaceutical platforms with high technical barriers to entry.

In the past, Ethypharm was acquired by Astorg in 2007 as part of its expansion strategy.

Ethypharm, which reported an EBITDA margin of [members only] in 2015, is valued in this transaction at an EV/EBITDA multiple of 10x–18x.

-> Deep-dive in Healthcare & Pharma market trends

Target

Headquartered in Saint-Cloud, Ethypharm is a specialized pharmaceutical group focused on the development and manufacturing of drug delivery systems and galenic forms. The entity maintains a strong therapeutic focus on the central nervous system, particularly in the treatment of pain and addiction, which accounts for nearly half of its total revenue. The business model is built on high-value clinical differentiation and an extensive international reach, with 66% of its commercial activity generated outside of France. The company operates through a global network of over 80 partners and maintains direct subsidiaries in key markets including the United States, Canada, the United Kingdom, Germany, and China. Historically, the firm has strengthened its portfolio through strategic acquisitions, such as Laboratoires Pharmaceutiques Dexo and the British specialist DB Ashbourne. Its value proposition centers on its specialized R&D capabilities and complex manufacturing processes that cater to global pharmaceutical standards.

Ent. Value

€500M–1.5bn

Equity Value

[members only]

Multiples

EV / Revenue

2x–6x

EV / EBITDA

10x–18x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2015
€250–500M
€50–100M
[members only]
2014
€250–500M
€50–100M
[members only]

Other operations with Ethypharm

Other operations with Ethypharm
DateAcquirerTargetCountrySector
04/2007ASTORGETHYPHARMFRANCEPharma & Biotech

Other operations with PAI Partners

Other operations with PAI Partners
DateAcquirerTargetCountrySector
10/2017PAI PARTNERSREFRESCONETHERLANDSBeverages
05/2017PAI PARTNERSELITECH GROUPFRANCEDiagnostic Equipment
06/2016PAI PARTNERSATOS MEDICALSWEDENMedical Consumables
02/2016ADB SAFEGATE / PAI PARTNERSSAFEGATE INTERNATIONALSWEDENAerospace, Naval & Defense
12/2015PAI PARTNERSGROUPE B&B HOTELSFRANCEHotels & Accommodation
06/2014PAI PARTNERSVPS HOLDINGSUNITED KINGDOMSecurity & Guarding
06/2014PAI PARTNERSLABEYRIE FINE FOODSFRANCEFood Products
06/2014PAI PARTNERSDOMUSVIFRANCENursing Homes
04/2014PAI PARTNERS / THE CARLYLE GROUPINNOVISTA (EX CST)FRANCESensors & Optics
04/2014PAI PARTNERSEURO MEDIA GROUPFRANCEAudiovisual Production

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
09/2016ARCHIMEDPOLYPLUSFRANCER&D Biotech
09/2016ARDIAN / IXO PRIVATE EQUITYLAGARRIGUEFRANCEImplants & Prosthetics
06/2016PAI PARTNERSATOS MEDICALSWEDENMedical Consumables
06/2016BRIDGEPOINT / RAISE / FLEXSTONE PARTNERSACTEONFRANCEMedical Devices
05/2016IK PARTNERSMARLE GROUPFRANCEImplants & Prosthetics
03/2016PSP INVESTMENTSANTELLIQFRANCEAnimal Health
03/2016CVCDOC GENERICIITALYGenerics / Labs
02/2016TE CONNECTIVITYCREGANNA MEDICALIRELANDMedical Devices
02/2016ASTORG / GOLDMAN SACHSHRA PHARMAFRANCEGenerics / Labs
07/2015PERRIGO COMPANYNATURWOHL PHARMA (YOKEBE)GERMANYGenerics / Labs

REFERENCES

Valuation range: EV €500M–1.5bn

Revenue range: €250–500M

EBITDA range: €50–100M

EV/Revenue range: 2x - 6x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Ethypharm by PAI Partners are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: ethypharm

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Ethypharm, a French company specialised in Pharma & Biotech, by PAI Partners in 2016, structured as a leveraged buyout (LBO). This followed an earlier holding cycle initiated in April 2007, when the company was acquired by Astorg.

How was the acquisition of Ethypharm by PAI Partners valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €500M–1.5bn band, its EV/EBITDA multiple within the 10x - 18x range, and its EV/revenue multiple within the 2x - 6x range. Exact figures are available to members.

What were Ethypharm’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Ethypharm generated annual revenue estimated in the €250–500M range and EBITDA in the €50–100M bracket (FY 2015). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction intelligence is supported by independent reporting from specialized financial publications, alongside a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.